1
|
Xu F, Ma C, Wang S, Li Q, Zhang Z, He M. Higher Atherogenic Index of Plasma Is Associated with Hyperuricemia: A National Longitudinal Study. Int J Endocrinol 2024; 2024:4002839. [PMID: 38410172 PMCID: PMC10896650 DOI: 10.1155/2024/4002839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/18/2023] [Revised: 02/02/2024] [Accepted: 02/03/2024] [Indexed: 02/28/2024] Open
Abstract
Background The association between atherogenic index of plasma (AIP) and hyperuricemia remains indistinct. This study was aimed to examine the relationship between AIP and hyperuricemia among the middle-aged and the elderly Chinese population. Methods Datasets were retrieved from the China Health and Retirement Longitudinal Study (CHARLS) survey conducted in 2011 and 2015. 13,021 participants in the CHARLS in 2011 and 7,017 participants involved both in 2011 and 2015 were included, respectively. The measurement of AIP and hyperuricemia was based on the test of fasting blood. Association between AIP and hyperuricemia was assessed by logistic regression, and the nonlinear association was examined by restricted cubic splines (RCS). The cutoff point of AIP was calculated using receiver operator curve (ROC). 1 : 1 propensity score matching (PSM) was adopted to further explore the relationship between AIP and hyperuricemia. Results In the section of a cross-sectional study, a positive association between AIP and hyperuricemia was found. The odds ratios (ORs) of hyperuricemia were 1.00 (reference), 1.52 (1.10-2.10), 1.80 (1.31-2.47), and 3.81 (2.84-5.11). Nonlinear association was not detected using RCS analysis. There were 664 hyperuricemia cases during the four years follow-up. The hyperuricemia prevalence was 9.5%. In the fully adjusted longitudinal analysis, the ORs for hyperuricemia across the quartiles of AIP were 1.00 (reference), 1.00 (0.74-1.37), 1.59 (1.20-2.11), and 2.55 (1.94-3.35), respectively. In the longitudinal analysis after PSM, the OR of hyperuricemia were 1.91 (1.45, 2.51) and 1.92 (1.45, 2.54) in the univariate and multivariate model, respectively. Conclusion AIP can predict the prevalence of hyperuricemia in the Chinese middle-aged and elderly population.
Collapse
Affiliation(s)
- Feifei Xu
- Department of Intensive Care Medicine, West China Hospital, Sichuan University, Chengdu, China
- Department of Critical Care Medicine, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu 610041, China
| | - Chengyong Ma
- Department of Intensive Care Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - Shouping Wang
- Department of Intensive Care Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - Qin Li
- Department of Intensive Care Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - Zhongwei Zhang
- Department of Intensive Care Medicine, West China Hospital, Sichuan University, Chengdu, China
| | - Min He
- Department of Intensive Care Medicine, West China Hospital, Sichuan University, Chengdu, China
| |
Collapse
|
2
|
Muszyński P, Dąbrowski EJ, Pasławska M, Niwińska M, Kurasz A, Święczkowski M, Tokarewicz J, Kuźma Ł, Kożuch M, Dobrzycki S. Hyperuricemia as a Risk Factor in Hypertension among Patients with Very High Cardiovascular Risk. Healthcare (Basel) 2023; 11:2460. [PMID: 37685494 PMCID: PMC10486932 DOI: 10.3390/healthcare11172460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2023] [Revised: 08/25/2023] [Accepted: 09/01/2023] [Indexed: 09/10/2023] Open
Abstract
Hypertension remains a global threat to public health, affecting the worldwide population. It is one of the most common risk factors for cardiovascular disease. Today's treatments focus on creating a hypotensive effect. However, there is a constant search for additional factors to reduce the potential of developing hypertension complications. These factors may act as a parallel treatment target with a beneficial effect in specific populations. Some studies suggest that uric acid may be considered such a factor. This study investigated the potential effect of uric acid concentrations over 5 mg/dL on the incidence of hypertension complications among patients with very high cardiovascular risk. A total of 705 patients with hypertension and very high cardiovascular risk were selected and included in the analysis. The patients were divided and compared according to serum uric acid levels. The study showed a higher occurrence of heart failure (OR = 1.7898; CI: 1.2738-2.5147; p = 0.0008), atrial fibrillation (OR = 3.4452; CI: 1.5414-7.7002; p = 0.0026) and chronic kidney disease (OR = 2.4470; CI: 1.3746-4.3558; p = 0.0024) among individuals with serum uric acid levels over 5 mg/dL, males and those with a BMI > 25 kg/m2. These findings suggest that even serum uric acid concentrations over 5 mg/dL may affect the prevalence of hypertension-related complications among patients with very high cardiovascular risk.
Collapse
Affiliation(s)
- Paweł Muszyński
- Department of Invasive Cardiology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland; (P.M.); (A.K.); (M.Ś.); (J.T.); (Ł.K.); (M.K.)
- Department of General and Experimental Pathology, Medical University of Białystok, Mickiewicza 2C, 15-230 Białystok, Poland
| | - Emil Julian Dąbrowski
- Department of Invasive Cardiology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland; (P.M.); (A.K.); (M.Ś.); (J.T.); (Ł.K.); (M.K.)
| | - Marta Pasławska
- Department of Pediatrics, Endocrinology, Diabetology with Cardiology Divisions, Medical University of Białystok, J. Waszyngtona 17, 15-274 Białystok, Poland;
| | - Marta Niwińska
- Department of Family Medicine, Medical University of Białystok, Mieszka I 4B, 15-054 Białystok, Poland;
| | - Anna Kurasz
- Department of Invasive Cardiology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland; (P.M.); (A.K.); (M.Ś.); (J.T.); (Ł.K.); (M.K.)
| | - Michał Święczkowski
- Department of Invasive Cardiology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland; (P.M.); (A.K.); (M.Ś.); (J.T.); (Ł.K.); (M.K.)
| | - Justyna Tokarewicz
- Department of Invasive Cardiology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland; (P.M.); (A.K.); (M.Ś.); (J.T.); (Ł.K.); (M.K.)
| | - Łukasz Kuźma
- Department of Invasive Cardiology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland; (P.M.); (A.K.); (M.Ś.); (J.T.); (Ł.K.); (M.K.)
| | - Marcin Kożuch
- Department of Invasive Cardiology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland; (P.M.); (A.K.); (M.Ś.); (J.T.); (Ł.K.); (M.K.)
| | - Sławomir Dobrzycki
- Department of Invasive Cardiology, Medical University of Białystok, M. Skłodowskiej-Curie 24A, 15-276 Białystok, Poland; (P.M.); (A.K.); (M.Ś.); (J.T.); (Ł.K.); (M.K.)
| |
Collapse
|
3
|
Prevalence of Hyperuricemia and Its Association with Cardiovascular Risk Factors and Subclinical Target Organ Damage. J Clin Med 2022; 12:jcm12010050. [PMID: 36614852 PMCID: PMC9820920 DOI: 10.3390/jcm12010050] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Revised: 12/05/2022] [Accepted: 12/16/2022] [Indexed: 12/24/2022] Open
Abstract
The role of uric acid levels in the cardiovascular continuum is not clear. Our objective is to analyze the prevalence of hyperuricemia (HU) and its association with cardiovascular risk factors (CVRF), subclinical target organ damage (sTOD), and cardiovascular diseases (CVD). We evaluated the prevalence of HU in 6.927 patients included in the baseline visit of the IBERICAN study. HU was defined as uric acid levels above 6 mg/dL in women, and 7 mg/dL in men. Using adjusted logistic regression models, the odds ratios were estimated according to CVRF, sTOD, and CVD. The prevalence of HU was 16.3%. The risk of HU was higher in patients with pathological glomerular filtration rate (aOR: 2.92), heart failure (HF) (aOR: 1.91), abdominal obesity (aOR: 1.80), hypertension (HTN) (aOR: 1.65), use of thiazides (aOR: 1.54), left ventricular hypertrophy (LVH) (aOR: 1.36), atrial fibrillation (AFIB) (aOR: 1.29), and albuminuria (aOR: 1.27). On the other hand, being female (aOR: 0.82) showed a reduced risk. The prevalence of HU was higher in men, in patients presenting CVRF such as HTN and abdominal obesity, and with co-existence of LVH, atrial fibrillation (AFIB), HF, and any form of kidney injury. These associations raise the possibility that HU forms part of the early stages of the cardiovascular continuum. This may influence its management in Primary Healthcare because the presence of HU could mean an increased CV risk in the patients.
Collapse
|
4
|
Wei W, Zhou LJ, Wang S, Zhang Z, Huang JY, Zhang Z, Zhang XP, Zhang XJ, Li J, Zhang YW. Katsuwonus pelamis Peptide and its Complexes Protect Zebrafish and Mice From Hyperuricemia Through Promoting Kidney Excretion of Uric Acid and Inhibiting Liver Xanthine Oxidase Activity. Front Chem 2022; 10:924371. [PMID: 35836673 PMCID: PMC9273819 DOI: 10.3389/fchem.2022.924371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2022] [Accepted: 05/18/2022] [Indexed: 11/13/2022] Open
Abstract
Katsuwonus pelamis peptide and its complexes have the effect of lowering uric acid (UA)-levels. To identify the effect and possible mechanisms, different concentrations of Katsuwonus pelamis peptide and its complexes were administered to the zebrafish and mice hyperuricemia models, and the UA level was measured. Meanwhile, the hyperuricemic mice were treated orally at 0.83, 1.67, and 5.00 mg/g body weight for 7 days with Katsuwonus pelamis peptide and the complexes groups, separately. The levels of serum UA (SUA), urinary UA (UUA), serum creatinine (SCR), blood urine nitrogen (BUN), and xanthine oxidase (XOD) activities were detected in each group. The results showed that the Katsuwonus pelamis peptide (125 μg/ml) and its complexes (83.3 and 250 μg/ml) effectively reduced UA level in zebrafish with hyperuricemia (p < 0.05). The Katsuwonus pelamis peptide at high concentration (5.00 mg/g) decreased the SUA level, SCR level, BUN level, and hepatic XOD activity, and the complexes (1.67 and 5.00 mg/g) significantly reduced the SUA level and hepatic XOD activity (p < 0.05) in the hyperuricemic mice. In addition, in a hyperuricemic mouse model, the UUA level was increased after treatment with Katsuwonus pelamis peptide and its complexes at high concentrations (p < 0.05). The total therapeutic effects in the Katsuwonus pelamis peptide complex group were better than those in the Katsuwonus pelamis peptide group. Thus, Katsuwonus pelamis peptide and its complexes may possibly be used to prevent hyperuricemia via promoting urate secretion and inhibiting XOD activity production.
Collapse
Affiliation(s)
- Wei Wei
- School of Pharmacy, Jiangsu University, Zhenjiang, China
| | - Li-Jian Zhou
- The People’s Hospital of Danyang, Danyang, China
| | - Shue Wang
- School of Public Health, Shandong University, Jinan, China
| | - Zheng Zhang
- Zhongshiduqing Biotechnology Co., Ltd., Heze, China
| | - Jia-Ying Huang
- School of Pharmacy, Jiangsu University, Zhenjiang, China
| | - Zhao Zhang
- Zhongshiduqing Biotechnology Co., Ltd., Heze, China
| | | | | | - Jie Li
- Zhongshiduqing Biotechnology Co., Ltd., Heze, China
| | - Ye-Wang Zhang
- School of Pharmacy, Jiangsu University, Zhenjiang, China
- *Correspondence: Ye-Wang Zhang,
| |
Collapse
|